...
首页> 外文期刊>Zeitschrift fur Arznei- und Gewurzpflanzen >Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis
【24h】

Diagnostics of progression of liver fibrosis in patients with non-alcoholic steatohepatitis combined with obesity and chronic calculous cholecystitis

机译:非酒精脂肪性肝炎患者患者肝纤维化进展诊断与肥胖和慢性光滑胆囊炎相结合

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the work is to investigate the diagnostic value of laboratory blood biomarkers - alanine aminotransferase, aspartate aminotransferase, oxyproline and prothrombin time in comparison with morphological indicators for diagnosis of the degree of liver fibrosis in patients with comorbid course of non-alcoholic steatohepatitis (NASH) combined with obesity and chronic calculous cholecystitis. The data of 22 patients with NASH combined with obesity and chronic calculous cholecystitis was analyzed by laboratory and morphological indicators. There were 6 (27.2%) men and 16 (72.8%) women among the patients. Liver biopsy was performed intra-operatively on performing surgical treatment of calculus cholecystitis. METAVIR and E. Brunt criteria were used in the histological diagnosis of NASH, as well as for determination of the stage of liver fibrosis (LF). Hepatic tissue fibrogenesis was assessed by serum values of total (OPT), free (OPF) and protein-bound (OPB) oxyproline, activity of indirect fibrosis markers - alanine aminotransferase (ALT), aspartate aminotransferase (AST), AST/ALT ratio and prothrombin time (PTT). As a mathematical tool for modeling, stepwise discriminant analysis was used. Fibrosis of the first stage (F1) was observed in 5 (22.7%) patients, the second stage of fibrosis (F2) - in 7 (31.8%), F3 stage of fibrosis - in 10 (45.5%) patients. Analysis of the morphological study of liver biopsy samples in examined patients with NASH indicates that established histological changes combine the signs of fatty and protein degeneration of hepatocytes, inflammation and necrosis in the lobules. Among the indicators included in the mathematical model the highest diagnostic significance can be attributed to the AST / ALT ratio (F = 9.03; p = 0.003) and the level of OPF (F = 5.67; p = 0.016), whereas OPB level has the lowest value (F = 2.94; p = 0.086). Evaluation of the accuracy of the method for determining of the LF phase based on the proposed algorithm showed that the frequency of correct detecting of F1 and F2 stages of LF was 100%, for the F3 stage - 90% (1 case attributed to the F2 stage). In general, the accuracy of the method was 95.5% (95% CI 86.8-100%), sensitivity - 90.0% (95% CI 71.4-100%), specificity - 100% (95% CI 92,5 - 100%), validity - 90.0%. Evaluation of the stage of LF in patients with NASH combined with obesity and chronic calculous cholecystitis, which was determined using discriminant functions calculated from laboratory data (OPT, OPF, OPB, ALT, AST / ALT ratio and PTT), is very much in line with the corresponding results of histopathological studies of liver biopsy samples.
机译:该作品的目的是研究实验室血液生物标志物 - 丙氨酸氨基转移酶,天冬氨酸氨基转移酶,氧脯氨酸氨基转移酶,氧脯氨酸和凝血酶原的诊断时间与非酒精脂肪虫病患者患者肝纤维化程度的形态学指标相比(纳什)结合肥胖和慢性光滑胆囊炎。通过实验室和形态学指标分析了22例纳什患有肥胖和慢性光滑胆囊炎的患者。患者中有6名(27.2%)男性和16名(72.8%)。肝脏活组织检查是在术中进行的,进行了对微积分胆囊炎的手术治疗。 Metavir和E.配备标准用于NASH的组织学诊断,以及测定肝纤维化(LF)的阶段。通过总(选择),游离(OPF)和蛋白质结合(OPB)氧化剂,间接纤维化标记物的活性 - 丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),AST / ALT比和蛋白凝血酶原时间(PTT)。作为用于建模的数学工具,使用逐步判别分析。在5例(22.7%)患者中,观察到第一阶段(F1)的纤维化,纤维化(F2)的第二阶段 - 在7(31.8%),纤维化的F3阶段 - 10(45.5%)患者。肝脏腹泻患者肝活检样品的形态学研究表明,肝细胞肝细胞脂肪和蛋白质退化的迹象结合了叶片中的脂肪和蛋白质退化的迹象。在数学模型中包含的指标中,最高的诊断意义可以归因于AST / ALT比(F = 9.03; P = 0.003)和OPF的水平(F = 5.67; P = 0.016),而opb级别具有最低值(f = 2.94; p = 0.086)。评估基于所提出的算法确定LF相的方法的准确性表明,对于F3阶段 - 90%(1例归因于F2,LF的F1和F2阶段的正确检测频率为100%阶段)。一般而言,该方法的准确性为95.5%(95%CI 86.8-100%),灵敏度 - 90.0%(95%CI 71.4-100%),特异性 - 100%(95%CI 92,5-100%) ,有效性 - 90.0%。使用从实验室数据(OPT,OPF,OPB,ALT,AST / ALT,AST / ALT,AST / ALT比率和PTT)计算的肥胖和慢性光滑胆囊炎的腹期患者中LF患者患者的评估肝活检样品组织病理学研究的相应结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号